NICE backs Akcea's Tegse­di; EMA re­stricts Lem­tra­da use while it probes safe­ty con­cerns

UK’s NICE has en­dorsed the use of Akcea’s in­ot­ersen (brand­ed as Tegse­di) to treat pa­tients with a rare in­her­it­ed con­di­tion called hered­i­tary transthyretin-re­lat­ed amy­loi­do­sis (hAT­TR), af­ter the Io­n­is $IONS sis­ter com­pa­ny of­fered the agency an “im­proved com­mer­cial agree­ment.” This counts as a win for Akcea, which has been com­pet­ing against Al­ny­lam’s $AL­NY On­pat­tro, al­though the dataset sup­port­ing its ap­proval is seen as a run­ner up to On­pat­tro. The UK has rough­ly 150 hAT­TR pa­tients, ac­cord­ing to NICE.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.